Article Versions Notes

Sho T, Suda G, Yamamoto Y, Furuya K, Baba M, Ogawa K, Kubo A, Tokuchi Y, Fu Q, Yang Z, et al. Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150. Cancers. 2022; 14(16):3938. https://doi.org/10.3390/cancers14163938

Sho, Takuya, Goki Suda, Yoshiya Yamamoto, Ken Furuya, Masaru Baba, Koji Ogawa, Akinori Kubo, Yoshimasa Tokuchi, Qingjie Fu, Zijian Yang, and et al. 2022. "Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150" Cancers 14, no. 16: 3938. https://doi.org/10.3390/cancers14163938

Sho, T., Suda, G., Yamamoto, Y., Furuya, K., Baba, M., Ogawa, K., Kubo, A., Tokuchi, Y., Fu, Q., Yang, Z., Kimura, M., Kitagataya, T., Maehara, O., Ohnishi, S., Nakamura, A., Yamada, R., Ohara, M., Kawagishi, N., Natsuizaka, M., ... Sakamoto, N. (2022). Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150. Cancers, 14(16), 3938. https://doi.org/10.3390/cancers14163938